-
Alternative name
ARF,CDKN2A, CDK4 inhibitor p16 INK4, CDK4 inhibitor p16INK4, CDK4I, CDKN2, CDKN2A, CMM2, INK4, INK4a, MLM, MTS 1, MTS1, Multiple tumor suppressor 1, p14, p14ARF, P16, p16 INK4, p16 INK4a, p16INK4, p16INK4a, P19, TP16 antibody
-
Catalog
A006064
-
Size100μg
-
Formliquid
-
Purity≥95% as determined by SDS-PAGE
-
StoragePBS with 0.02% sodium azide and 50% glycerol pH 7.3 , -20℃ for 24 months (Avoid repeated freeze / thaw cycles.)
-
ClonalityPolyclonal Antibody
-
Host Rabbit
-
Species ReactivityHuman,Mouse ,Rat
-
Applications Tested/SuitableELISA,WB,IF,IP,IHC,FC
-
PurificationImmunogen affinity purified
-
Immunogencyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
-
IHCImmunohistochemistry of paraffin-embedded human tonsillitis tissue slide using A006064( P16-INK4A Antibody) at dilution of 1:200 heat mediated antigen retrieved with Tris-EDTA buffer(pH9).
-
Western BlotHEK-293 cells were subjected to SDS PAGE followed by western blot with A006064(P16 antibody) at dilution of 1:1000
-
Recommended dilutionWB:1:500-1:5000;IP:1:500-1:5000;IHC:1:50-1:500;IF:1:20-1:200
-
Product Description specificalCDKN2A generates several transcript variants which differ in their first exons. At least three alternatively-spliced variants encoding distinct proteins have been reported, and two are related, named p16-INK4 and p14 respetively, sharing 50% identity. The third one is completely stuctually un-related, called p14(ARF) or p19(ARF). 10883-1-AP reacted with p16 specifically. P16 plays an important role in regulating the cell cycle, and mutations in p16 increase the risk of developing a variety of cancers, notably melanoma.
-
Gene nameCDKN2A
-
Uniprot IDP42771
-
Calculated M.W.16kDa
-
Observed M.W.16-18 kDa
-